A regulatory and scientific framework for analytical quality by design in pharmaceutical analysis

Area of Science:

• Pharmaceutical Science
• Analytical Chemistry
• Process Engineering

Background:

• Traditional analytical method development relies on trial-and-error, leading to inefficiencies.
• Quality-by-Design (QbD) offers a systematic, risk-based framework for analytical method development.
• The Analytical Target Profile (ATP) is central to QbD, defining method performance criteria.

Purpose of the Study:

• To elucidate the principles and application of QbD in analytical method development.
• To highlight the role of risk assessment and statistical tools in QbD.
• To explain the concept and importance of the Method Operable Design Region (MODR).

Main Methods:

• Systematic literature review and data organization using Microsoft Excel and EndNote.
• Database searches across PubMed, Web of Science, Elsevier, and Google Scholar.
• Application of risk assessment tools (e.g., Ishikawa diagram, FMEA) and statistical methods (Design of Experiments - DoE).

Main Results:

• QbD facilitates the identification of Critical Quality Attributes (CQAs) and Critical Method Parameters (CMPs).
• Design of Experiments (DoE) enables optimization of key variables and defines the Method Operable Design Region (MODR).
• MODR defines operational space for reliable results, allowing post-approval modifications.

Conclusions:

• QbD provides a robust scientific framework for developing reliable and flexible analytical methods.
• Integration of QbD principles enhances drug manufacturing quality and efficiency.
• Lifecycle management and real-time monitoring within QbD ensure continuous quality improvement.